Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $3.779 million which beat the analyst consensus estimate of $1.033 million by 265.83 percent. This is a 203.29 percent increase over sales of $1.246 million the same period last year.